Form 8-K

8-K — JOHNSON & JOHNSON

Accession: 0000200406-26-000189

Filed: 2026-10-13

Period: 2026-10-13

CIK: 0000200406

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — jnj-20261013.htm (Primary)

EX-99.1 (a2026q3exhibit991.htm)

EX-99.2 (a2026q3exhibit992.htm)

GRAPHIC (image_1a.jpg)

GRAPHIC (jnjlogoa.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: jnj-20261013.htm · Sequence: 1

jnj-20261013

0000200406false00002004062026-10-132026-10-130000200406us-gaap:CommonStockMember2026-10-132026-10-130000200406jnj:A1.150NotesDueNovember2028Member2026-10-132026-10-130000200406jnj:A2.700NotesDueFebruary2029Member2026-10-132026-10-130000200406jnj:A3.20NotesDueJune2032Member2026-10-132026-10-130000200406jnj:A3.050NotesDueFebruary2033Member2026-10-132026-10-130000200406jnj:A1.650NotesDueMay2035Member2026-10-132026-10-130000200406jnj:A3.350NotesDueJune2036Member2026-10-132026-10-130000200406jnj:A3.350NotesDueFebruary2037Member2026-10-132026-10-130000200406jnj:A3.550NotesDueJune2044Member2026-10-132026-10-130000200406jnj:A3.600NotesDueFebruary2045Member2026-10-132026-10-130000200406jnj:A3.700NotesDueFebruary2055Member2026-10-132026-10-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

October 13, 2026

Johnson & Johnson

(Exact name of registrant as specified in its charter)

New Jersey

1-3215

22-1024240

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $1.00

JNJ

New York Stock Exchange

1.150% Notes Due November 2028

JNJ28

New York Stock Exchange

2.700% Notes due February 2029

JNJ29B

New York Stock Exchange

3.200% Notes Due June 2032

JNJ32

New York Stock Exchange

3.050% Notes due February 2033

JNJ33B

New York Stock Exchange

1.650% Notes Due May 2035

JNJ35

New York Stock Exchange

3.350% Notes Due June 2036

JNJ36A

New York Stock Exchange

3.350% Notes due February 2037

JNJ37B

New York Stock Exchange

3.550% Notes Due June 2044

JNJ44

New York Stock Exchange

3.600% Notes due February 2045

JNJ45

New York Stock Exchange

3.700% Notes due February 2055

JNJ55

New York Stock Exchange

Item 2.02 Results of operations and financial condition

On October 13, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 27, 2026.

Item 9.01 Financial statements and exhibits

(d) Exhibits.

Exhibit No. Description of Exhibit

99.1

Press Release dated October 13, 2026 for the period ended September 27, 2026

99.2

Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 13, 2026

JOHNSON & JOHNSON

(Registrant)

By:

/s/ Robert J. Decker, Jr.

Robert J. Decker, Jr.

Controller

(Principal Accounting Officer)

EX-99.1

Filename: a2026q3exhibit991.htm · Sequence: 2

Document

Exhibit 99.1

Media contact:

media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

For immediate release

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

•2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*

•2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals

•Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint

•Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer

New Brunswick, N.J. (October 13, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.

“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”

Overall financial results

($ in Millions, except EPS)

2026

2025

% Change

Reported Sales

$25,399

$23,993

5.9

Net Earnings

$210

$5,152

(95.9)

EPS (diluted)

$0.09

$2.12

(95.8)

Non-GAAP* ($ in Millions, except EPS)

2026

2025

% Change

Operational Sales1,2

6.0

Adjusted Operational Sales1,3

6.1

Adjusted Net Earnings1,4

$6,339

$6,801

(6.8)

Adjusted EPS (diluted)1,4

$2.59

$2.80

(7.5)

Free Cash Flow5,6

~$15,100

$14,226

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

4Excludes intangible amortization expense and special items

5Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

6Third-quarter YTD 2026 is estimated as of October 13, 2026

Note: values may have been rounded

Regional sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

U.S.

$14,959

$13,708

9.1

—

9.1

International

10,440

10,285

1.5

1.8

(0.3)

1.9

Worldwide

$25,399

$23,993

5.9

6.0

(0.1)

6.1

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

Innovative Medicine

$16,757

$15,563

7.7

7.9

(0.2)

8.0

MedTech

8,642

8,430

2.5

0.0

2.5

Worldwide

$25,399

$23,993

5.9

6.0

(0.1)

6.1

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Third-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

October 2026

July 29, 2026

Adjusted Operational Sales1,2

Change vs. Prior Year / Mid-point

6.4% – 6.8% / 6.6%

6.2% – 6.8% / 6.5%

Operational Sales2 / Mid-point

Change vs. Prior Year / Mid-point

$100.5B – $100.9B /$100.7B

6.7% – 7.1% / 6.9%

$100.3B – $100.9B / $100.6B

6.5% – 7.1% / 6.8%

Estimated Reported Sales3/ Mid-point

Change vs. Prior Year / Mid-point

$101.0B – $101.4B / $101.2B

7.2% – 7.6% / 7.4%

$100.8B – $101.4B / $101.1B

7.0% – 7.6% / 7.3%

Adjusted Operational EPS (Diluted)2,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.95 – $11.05 / $11.00

1.5% – 2.4% / 2.0%

$10.86 – $11.01 / $10.94

0.7% – 2.1% / 1.4%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$11.05 – $11.15 / $11.10

2.4% – 3.3% / 2.9%

$10.96 – $11.11 / $11.04

1.6% – 3.0% / 2.3%

1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2Non-GAAP financial measure; excludes the impact of translational currency

3Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only)

4Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.

Regulatory

Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses1

Press Release

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Press Release

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Press Release

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Press Release

Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

Press Release

Data Releases

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis1

Press Release

Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy1

Press Release

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)

Press Release

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Press Release

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Press Release

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma

Press Release

CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

Press Release

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Press Release

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Press Release

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

Press Release

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Press Release

Other

New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause1

Press Release

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Press Release

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Press Release

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Press Release

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Press Release

1Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

EX-99.2

Filename: a2026q3exhibit992.htm · Sequence: 3

Document

Exhibit 99.2

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) THIRD QUARTER

Percent Change

Sales to customers by geographic area 2026 2025 Total Operations Currency

U.S.

$14,959 13,708 9.1 % 9.1 —

Europe

5,405 5,440 (0.6) 1.0 (1.6)

Western Hemisphere excluding U.S.

1,385 1,231 12.5 8.0 4.5

Asia-Pacific, Africa

3,650 3,614 1.0 1.0 0.0

International

10,440 10,285 1.5 1.8 (0.3)

Worldwide

$25,399 23,993 5.9 % 6.0 (0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) NINE MONTHS

Percent Change

Sales to customers by geographic area 2026 2025 Total Operations Currency

U.S.

$42,822 39,557 8.3 % 8.3 —

Europe

16,979 15,937 6.5 2.3 4.2

Western Hemisphere excluding U.S.

3,987 3,604 10.6 4.5 6.1

Asia-Pacific, Africa

10,983 10,531 4.3 3.6 0.7

International

31,949 30,072 6.2 3.0 3.2

Worldwide

$74,771 69,629 7.4 % 6.0 1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) THIRD QUARTER

Percent Change

Sales to customers by segment of business 2026 2025 Total Operations Currency

Innovative Medicine

U.S.

$ 10,447 9,402 11.1 % 11.1 —

International

6,310 6,161 2.4 3.0 (0.6)

16,757 15,563 7.7 7.9 (0.2)

MedTech

U.S.

4,512 4,306 4.8 4.8 —

International

4,130 4,124 0.1 0.1 0.0

8,642 8,430 2.5 2.5 0.0

U.S.

14,959 13,708 9.1 9.1 —

International

10,440 10,285 1.5 1.8 (0.3)

Worldwide

$ 25,399 23,993 5.9 % 6.0 (0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) NINE MONTHS

Percent Change

Sales to customers by segment of business 2026 2025 Total Operations Currency

Innovative Medicine

U.S.

$ 29,297 26,655 9.9 % 9.9 —

International

19,270 17,983 7.2 3.6 3.6

48,567 44,638 8.8 7.4 1.4

MedTech

U.S.

13,525 12,902 4.8 4.8 —

International

12,679 12,089 4.9 2.2 2.7

26,204 24,991 4.9 3.5 1.4

U.S.

42,822 39,557 8.3 8.3 —

International

31,949 30,072 6.2 3.0 3.2

Worldwide

$ 74,771 69,629 7.4 % 6.0 1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures) THIRD QUARTER

2026 2025 Percent

Increase

(Decrease)

Amount Percent

to Sales Amount Percent

to Sales

Sales to customers $ 25,399 100.0 $ 23,993 100.0 5.9

Cost of products sold 8,097 31.9 7,303 30.4 10.9

Gross Profit 17,302 68.1 16,690 69.6 3.7

Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1

Research and development expense 4,652 18.3 3,672 15.3 26.7

In-process research and development impairments 339 1.4 — —

Interest (income) expense, net 31 0.1 18 0.1

Other (income) expense, net 5,780 22.8 (478) (2.0)

Restructuring 181 0.7 63 0.3

Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5)

(Benefit from)/Provision for taxes on income (176) (0.7) 2,341 9.7 (107.5)

Net earnings $ 210 0.8 $ 5,152 21.5 (95.9)

Net earnings per share (Diluted) $ 0.09 $ 2.12 (95.8)

Average shares outstanding (Diluted) 2,448.6 2,428.6

Effective tax rate (517.6) % 31.2 %

Adjusted earnings before provision for taxes and net earnings (1) (A)

Earnings before provision for taxes on income

$ 7,672 30.2 $ 8,436 35.2

(9.1)

Net earnings

$ 6,339 25.0 $ 6,801 28.3

(6.8)

Net earnings per share (Diluted)

$ 2.59

$ 2.80

(7.5)

Effective tax rate

17.4 %

19.4 %

(1) See Reconciliation of Non-GAAP Financial Measures.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures) NINE MONTHS

2026 2025 Percent

Increase

(Decrease)

Amount Percent

to Sales Amount Percent

to Sales

Sales to customers $ 74,771 100.0 $ 69,629 100.0 7.4

Cost of products sold 24,254 32.4 22,288 32.0 8.8

Gross Profit 50,517 67.6 47,341 68.0 6.7

Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8

Research and development expense 11,832 15.8 10,413 15.0 13.6

In-process research and development impairments 375 0.5 — —

Interest (income) expense, net 136 0.2 (62) (0.1)

Other (income) expense, net 6,405 8.6 (7,692) (11.1)

Restructuring 247 0.3 144 0.2

Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8)

Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8)

Net earnings $ 10,979 14.7 $ 21,688 31.1 (49.4)

Net earnings per share (Diluted) $ 4.49 $ 8.94 (49.8)

Average shares outstanding (Diluted) 2,445.8 2,424.8

Effective tax rate 14.0 % 21.5 %

Adjusted earnings before provision for taxes and net earnings (1) (A)

Earnings before provision for taxes on income

$ 24,153 32.3 $ 24,635 35.4

(2.0)

Net earnings

$ 20,034 26.8 $ 20,206 29.0

(0.9)

Net earnings per share (Diluted)

$ 8.19

$ 8.33

(1.7)

Effective tax rate

17.1 %

18.0 %

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

THIRD QUARTER NINE MONTHS

(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025

Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688

Pre-tax Adjustments

Litigation related 5,519 15 6,116 (6,894)

Intangible Asset Amortization expense 1,240 1,048 3,732 3,435

Restructuring related 1

195 168 533 302

Orthopaedics separation related 369 — 746 —

Acquisition, integration and divestiture related (34) 97 142 475

(Gains)/losses on securities 10 (387) (262) (327)

IPR&D impairments 339 — 375 —

Other — 2 — 29

Tax Adjustments

Tax impact on special item adjustments 2

(1,677) (168) (2,469) 826

Tax legislation and other tax related 168 874 142 672

Adjusted Net Earnings, after tax $6,339 $6,801 $20,034 $20,206

Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8

Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33

Operational adjusted net earnings per share (Diluted) $2.61 $8.04

Notes:

1In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.

2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Third quarter 2026 actual vs. 2025 actual

Segments

Innovative Medicine MedTech Total

WW As Reported 7.7 % 2.5 % 5.9 %

U.S. 11.1 % 4.8 % 9.1 %

International 2.4 % 0.1 % 1.5 %

WW Currency (0.2) 0.0 (0.1)

U.S. — — —

International (0.6) 0.0 (0.3)

WW Operational 7.9 % 2.5 % 6.0 %

U.S. 11.1 % 4.8 % 9.1 %

International 3.0 % 0.1 % 1.8 %

All Other Acquisitions and Divestitures (A&D) 0.1 0.0 0.1

U.S. 0.0 0.0 0.0

International 0.2 0.0 0.1

WW Adjusted Operational Ex A&D 8.0 % 2.5 % 6.1 %

U.S. 11.1 % 4.8 % 9.1 %

International 3.2 % 0.1 % 1.9 %

Note: Percentages are based on actual, non-rounded figures and may not sum

(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Nine months 2026 actual vs. 2025 actual

Segments

Innovative Medicine MedTech Total

WW As Reported 8.8 % 4.9 % 7.4 %

U.S. 9.9 % 4.8 % 8.3 %

International 7.2 % 4.9 % 6.2 %

WW Currency 1.4 1.4 1.4

U.S. — — —

International 3.6 2.7 3.2

WW Operational 7.4 % 3.5 % 6.0 %

U.S. 9.9 % 4.8 % 8.3 %

International 3.6 % 2.2 % 3.0 %

Caplyta (0.6) (0.4)

U.S. (1.0) (0.7)

International 0.0 0.0

All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1

U.S. 0.0 0.1 0.0

International 0.2 0.0 0.1

WW Adjusted Operational Ex A&D 6.9 % 3.6 % 5.7 %

U.S. 8.9 % 4.9 % 7.6 %

International 3.8 % 2.2 % 3.1 %

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)

ONCOLOGY

US $ 4,267 3,468 23.0 % 23.0 % — %

Intl 3,335 3,060 9.0 9.5 (0.5)

WW 7,602 6,529 16.4 16.7 (0.3)

DARZALEX

US 2,528 2,088 21.1 21.1 —

Intl 1,711 1,584 8.0 8.5 (0.5)

WW 4,239 3,672 15.4 15.6 (0.2)

CARVYKTI

US 472 396 19.4 19.4 —

Intl 238 128 85.3 84.1 1.2

WW 710 524 35.5 35.2 0.3

TECVAYLI

US 236 115 * * —

Intl 77 62 24.0 25.9 (1.9)

WW 312 177 76.6 77.3 (0.7)

TALVEY

US 112 85 31.6 31.6 —

Intl 59 37 62.9 66.9 (4.0)

WW 171 122 40.9 42.1 (1.2)

RYBREVANT / LAZCLUZE

US 201 136 47.9 47.9 —

Intl 119 61 94.5 98.3 (3.8)

WW 320 198 62.3 63.5 (1.2)

ERLEADA

US 423 378 11.8 11.8 —

Intl 600 558 7.7 7.7 0.0

WW 1,023 936 9.4 9.4 0.0

IMBRUVICA

US 145 211 (31.6) (31.6) —

Intl 420 483 (13.2) (12.6) (0.6)

WW 563 695 (18.8) (18.4) (0.4)

OTHER ONCOLOGY(3)

US 149 61 * * —

Intl 111 147 (24.4) (23.9) (0.5)

WW 262 207 26.3 26.7 (0.4)

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

IMMUNOLOGY

US $ 2,804 2,676 4.8 % 4.8 % — %

Intl 1,417 1,493 (5.1) (4.8) (0.3)

WW 4,221 4,168 1.3 1.4 (0.1)

TREMFYA

US 1,772 989 79.1 79.1 —

Intl 624 434 43.7 43.4 0.3

WW 2,396 1,424 68.3 68.2 0.1

SIMPONI / SIMPONI ARIA

US 269 309 (13.2) (13.2) —

Intl 299 377 (20.6) (20.3) (0.3)

WW 568 687 (17.3) (17.1) (0.2)

REMICADE

US 258 326 (20.8) (20.8) —

US Exports(4)

12 19 (37.1) (37.1) —

Intl 124 132 (6.2) (7.5) 1.3

WW 394 476 (17.3) (17.6) 0.3

STELARA

US 368 1,022 (64.0) (64.0) —

Intl 349 549 (36.5) (35.5) (1.0)

WW 716 1,570 (54.4) (54.0) (0.4)

OTHER IMMUNOLOGY

US 126 12 * * —

Intl 21 0 * * *

WW 147 12 * * *

NEUROSCIENCE

US 1,733 1,367 26.8 26.8 —

Intl 642 658 (2.4) (1.7) (0.7)

WW 2,375 2,024 17.3 17.6 (0.3)

SPRAVATO

US 559 405 37.9 37.9 —

Intl 66 53 22.7 21.4 1.3

WW 624 459 36.1 36.0 0.1

CAPLYTA

US 398 240 66.1 66.1 —

Intl — — — — —

WW 398 240 66.1 66.1 —

INVEGA SUSTENNA / XEPLION / INVEGA

TRINZA / TREVICTA

US 739 664 11.4 11.4 —

Intl 258 267 (3.0) (2.4) (0.6)

WW 998 929 7.3 7.5 (0.2)

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CONCERTA / methylphenidate

US $ 6 14 (56.3) % (56.3) % — %

Intl 138 127 8.1 8.9 (0.8)

WW 143 140 2.1 2.9 (0.8)

OTHER NEUROSCIENCE

US 32 46 (30.6) (30.6) —

Intl 180 210 (14.3) (13.1) (1.2)

WW 212 256 (17.3) (16.2) (1.1)

PULMONARY HYPERTENSION (PH)

US 588 815 (27.8) (27.8) —

Intl 309 300 2.9 4.1 (1.2)

WW 897 1,115 (19.5) (19.2) (0.3)

UPTRAVI

US 383 392 (2.2) (2.2) —

Intl 100 92 8.9 8.4 0.5

WW 483 484 (0.1) (0.2) 0.1

OPSUMIT / OPSYNVI

US 193 409 (52.8) (52.8) —

Intl 179 168 5.9 7.8 (1.9)

WW 372 578 (35.7) (35.2) (0.5)

OTHER PULMONARY HYPERTENSION

US 12 13 (7.3) (7.3) —

Intl 30 39 (23.8) (21.2) (2.6)

WW 42 53 (19.7) (17.7) (2.0)

INFECTIOUS DISEASES (ID)

US 317 326 (2.7) (2.7) —

Intl 496 501 (1.2) (0.1) (1.1)

WW 813 829 (1.8) (1.1) (0.7)

EDURANT / rilpivirine

US 5 7 (31.6) (31.6) —

Intl 382 378 1.0 2.4 (1.4)

WW 386 385 0.4 1.8 (1.4)

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US 307 315 (2.5) (2.5) —

Intl 74 81 (8.9) (7.7) (1.2)

WW 381 397 (3.8) (3.6) (0.2)

OTHER INFECTIOUS DISEASES

US 5 4 29.9 29.9 —

Intl 40 42 (6.2) (7.9) 1.7

WW 46 47 (3.0) (4.5) 1.5

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)

US $ 736 750 (1.9) % (1.9) % — %

Intl 112 149 (24.3) (23.8) (0.5)

WW 849 899 (5.6) (5.5) (0.1)

XARELTO

US 653 635 2.7 2.7 —

Intl — — — — —

WW 653 635 2.7 2.7 —

OTHER

US 84 115 (27.2) (27.2) —

Intl 112 149 (24.3) (23.8) (0.5)

WW 197 264 (25.5) (25.3) (0.2)

TOTAL PH, ID, CVM

US 1,643 1,891 (13.2) (13.2) —

Intl 917 950 (3.5) (2.5) (1.0)

WW 2,560 2,843 (9.9) (9.6) (0.3)

TOTAL INNOVATIVE MEDICINE

US 10,447 9,402 11.1 11.1 —

Intl 6,310 6,161 2.4 3.0 (0.6)

WW $16,757 15,563 7.7 % 7.9 % (0.2) %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)

CARDIOVASCULAR

US $ 1,397 1,306 7.0 % 7.0 % — %

Intl 910 908 0.2 (0.2) 0.4

WW 2,307 2,213 4.3 4.1 0.2

ELECTROPHYSIOLOGY

US 771 720 7.0 7.0 —

Intl 717 698 2.8 1.8 1.0

WW 1,487 1,418 4.9 4.4 0.5

ABIOMED

US 335 336 (0.3) (0.3) —

Intl 78 86 (10.4) (6.5) (3.9)

WW 412 423 (2.3) (1.5) (0.8)

SHOCKWAVE

US 261 220 18.8 18.8 —

Intl 64 59 9.3 11.2 (1.9)

WW 325 278 16.8 17.2 (0.4)

OTHER CARDIOVASCULAR

US 31 30 3.6 3.6 —

Intl 50 65 (21.9) (23.1) 1.2

WW 81 95 (13.9) (14.7) 0.8

SURGERY

US 1,070 1,031 3.7 3.7 —

Intl 1,459 1,511 (3.4) (4.2) 0.8

WW 2,528 2,542 (0.6) (1.0) 0.4

ADVANCED

US 500 477 5.1 5.1 —

Intl 654 688 (5.0) (5.7) 0.7

WW 1,155 1,165 (0.9) (1.3) 0.4

GENERAL

US 568 555 2.4 2.4 —

Intl 805 823 (2.2) (3.0) 0.8

WW 1,373 1,378 (0.3) (0.8) 0.5

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

THIRD QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)(Continued)

VISION

US $596 571 4.3 % 4.3 % — %

Intl 865 828 4.4 5.6 (1.2)

WW 1,461 1,400 4.4 5.1 (0.7)

CONTACT LENSES / OTHER

US 465 456 1.9 1.9 —

Intl 588 562 4.7 6.2 (1.5)

WW 1,053 1,018 3.5 4.3 (0.8)

SURGICAL

US 132 116 13.6 13.6 —

Intl 276 266 3.8 4.3 (0.5)

WW 408 383 6.8 7.1 (0.3)

ORTHOPAEDICS

US 1,448 1,396 3.8 3.8 —

Intl 898 878 2.2 2.9 (0.7)

WW 2,345 2,274 3.2 3.4 (0.2)

HIPS

US 271 262 3.5 3.5 —

Intl 148 144 2.6 3.0 (0.4)

WW 419 405 3.1 3.3 (0.2)

KNEES

US 221 216 2.1 2.1 —

Intl 165 160 3.0 4.4 (1.4)

WW 386 377 2.5 3.1 (0.6)

TRAUMA

US 555 512 8.6 8.6 —

Intl 288 281 2.4 2.8 (0.4)

WW 844 793 6.4 6.5 (0.1)

SPINE, SPORTS & OTHER

US 401 406 (1.2) (1.2) —

Intl 296 293 1.3 2.0 (0.7)

WW 697 698 (0.1) 0.1 (0.2)

TOTAL MEDTECH

US 4,512 4,306 4.8 4.8 —

Intl 4,130 4,124 0.1 0.1 0.0

WW $8,642 8,430 2.5 % 2.5 % 0.0 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)

ONCOLOGY

US $11,951 9,866 21.1 % 21.1 % — %

Intl 10,030 8,652 15.9 11.9 4.0

WW 21,981 18,519 18.7 16.8 1.9

DARZALEX

US 7,171 5,934 20.9 20.9 —

Intl 5,239 4,514 16.1 11.9 4.2

WW 12,410 10,448 18.8 17.0 1.8

CARVYKTI

US 1,377 1,072 28.5 28.5 —

Intl 587 260 * * *

WW 1,964 1,332 47.4 45.5 1.9

TECVAYLI

US 549 334 64.4 64.4 —

Intl 225 160 40.6 37.7 2.9

WW 774 494 56.7 55.7 1.0

TALVEY

US 325 235 38.1 38.1 —

Intl 172 79 * * *

WW 497 314 58.3 57.5 0.8

RYBREVANT / LAZCLUZE

US 566 388 46.1 46.1 —

Intl 300 130 * * *

WW 866 518 67.4 67.5 (0.1)

ERLEADA

US 1,161 1,048 10.8 10.8 —

Intl 1,806 1,567 15.3 10.8 4.5

WW 2,967 2,615 13.5 10.8 2.7

IMBRUVICA

US 437 685 (36.3) (36.3) —

Intl 1,386 1,453 (4.7) (8.7) 4.0

WW 1,822 2,139 (14.8) (17.5) 2.7

OTHER ONCOLOGY(3)

US 365 171 * * —

Intl 314 488 (35.7) (36.0) 0.3

WW 680 659 3.2 2.9 0.3

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

IMMUNOLOGY

US $7,031 7,377 (4.7) % (4.7) % — %

Intl 4,414 4,492 (1.7) (4.9) 3.2

WW 11,445 11,868 (3.6) (4.8) 1.2

TREMFYA

US 4,279 2,384 79.5 79.5 —

Intl 1,771 1,181 49.9 44.7 5.2

WW 6,050 3,566 69.7 67.9 1.8

SIMPONI / SIMPONI ARIA

US 798 906 (11.9) (11.9) —

Intl 1,035 1,130 (8.4) (11.4) 3.0

WW 1,833 2,036 (10.0) (11.6) 1.6

REMICADE

US 742 923 (19.6) (19.6) —

US Exports(4)

40 63 (36.6) (36.6) —

Intl 372 413 (9.8) (12.9) 3.1

WW 1,154 1,398 (17.5) (18.4) 0.9

STELARA

US 924 3,081 (70.0) (70.0) —

Intl 1,188 1,768 (32.8) (34.9) 2.1

WW 2,112 4,848 (56.4) (57.2) 0.8

OTHER IMMUNOLOGY

US 249 21 * * —

Intl 48 0 * * *

WW 297 21 * * *

NEUROSCIENCE

US 4,886 3,712 31.6 31.6 —

Intl 2,001 2,011 (0.5) (3.0) 2.5

WW 6,887 5,722 20.3 19.5 0.8

SPRAVATO

US 1,479 1,047 41.3 41.3 —

Intl 197 146 34.8 28.1 6.7

WW 1,676 1,193 40.5 39.7 0.8

CAPLYTA(5)

US 1,029 451 * * —

Intl — — — — —

WW 1,029 451 * * —

INVEGA SUSTENNA / XEPLION / INVEGA

TRINZA / TREVICTA

US 2,235 2,021 10.6 10.6 —

Intl 816 804 1.5 (0.8) 2.3

WW 3,051 2,824 8.0 7.4 0.6

CONCERTA / methylphenidate

US 40 76 (47.3) (47.3) —

Intl 386 376 2.4 1.1 1.3

WW 425 452 (5.9) (7.0) 1.1

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

OTHER NEUROSCIENCE

US $ 104 119 (12.6) % (12.6) % — %

Intl 602 684 (12.0) (14.5) 2.5

WW 706 803 (12.1) (14.2) 2.1

PULMONARY HYPERTENSION (PH)

US 2,233 2,358 (5.3) (5.3) —

Intl 942 895 5.2 2.9 2.3

WW 3,175 3,253 (2.4) (3.0) 0.6

UPTRAVI

US 1,154 1,139 1.3 1.3 —

Intl 306 272 12.7 7.9 4.8

WW 1,460 1,411 3.5 2.6 0.9

OPSUMIT / OPSYNVI

US 1,042 1,175 (11.3) (11.3) —

Intl 538 507 6.0 4.4 1.6

WW 1,580 1,682 (6.1) (6.6) 0.5

OTHER PULMONARY HYPERTENSION

US 37 44 (15.5) (15.5) —

Intl 98 116 (15.6) (15.3) (0.3)

WW 135 160 (15.6) (15.4) (0.2)

INFECTIOUS DISEASES (ID)

US 959 961 (0.2) (0.2) —

Intl 1,506 1,472 2.3 (1.7) 4.0

WW 2,465 2,434 1.3 (1.1) 2.4

EDURANT / rilpivirine

US 15 21 (30.1) (30.1) —

Intl 1,131 1,082 4.5 0.6 3.9

WW 1,145 1,103 3.8 0.0 3.8

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US 937 932 0.6 0.6 —

Intl 259 264 (1.9) (6.2) 4.3

WW 1,196 1,196 0.0 (0.9) 0.9

OTHER INFECTIOUS DISEASES

US 7 8 (11.4) (11.4) —

Intl 116 126 (8.0) (11.7) 3.7

WW 124 135 (8.2) (11.7) 3.5

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)

US $ 2,235 2,381 (6.1) % (6.1) % — %

Intl 378 461 (17.9) (20.9) 3.0

WW 2,614 2,842 (8.0) (8.5) 0.5

XARELTO

US 1,959 1,946 0.7 0.7 —

Intl — — — — —

WW 1,959 1,946 0.7 0.7 —

OTHER

US 276 435 (36.5) (36.5) —

Intl 378 461 (17.9) (20.9) 3.0

WW 655 896 (26.9) (28.5) 1.6

TOTAL PH, ID, CVM

US 5,428 5,700 (4.8) (4.8) —

Intl 2,826 2,828 (0.1) (3.4) 3.3

WW 8,254 8,529 (3.2) (4.3) 1.1

TOTAL INNOVATIVE MEDICINE

US 29,297 26,655 9.9 9.9 —

Intl 19,270 17,983 7.2 3.6 3.6

WW $ 48,567 44,638 8.8 % 7.4 % 1.4 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)

CARDIOVASCULAR

US $ 4,222 3,931 7.4 % 7.4 % — %

Intl 2,866 2,698 6.2 3.4 2.8

WW 7,088 6,629 6.9 5.8 1.1

ELECTROPHYSIOLOGY

US 2,290 2,145 6.8 6.8 —

Intl 2,219 2,064 7.5 4.3 3.2

WW 4,509 4,209 7.1 5.6 1.5

ABIOMED

US 1,066 1,035 3.0 3.0 —

Intl 275 256 7.2 5.4 1.8

WW 1,340 1,291 3.8 3.5 0.3

SHOCKWAVE

US 771 659 17.0 17.0 —

Intl 194 169 14.8 15.1 (0.3)

WW 965 828 16.6 16.6 0.0

OTHER CARDIOVASCULAR

US 96 93 3.2 3.2 —

Intl 177 209 (15.0) (17.7) 2.7

WW 273 302 (9.4) (11.3) 1.9

SURGERY

US 3,210 3,076 4.3 4.3 —

Intl 4,483 4,417 1.5 (1.6) 3.1

WW 7,692 7,493 2.7 0.8 1.9

ADVANCED

US 1,476 1,411 4.7 4.7 —

Intl 1,991 1,991 0.0 (2.9) 2.9

WW 3,467 3,402 1.9 0.2 1.7

GENERAL

US 1,733 1,666 4.0 4.0 —

Intl 2,492 2,426 2.7 (0.6) 3.3

WW 4,225 4,092 3.3 1.3 2.0

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

NINE MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)(Continued)

VISION

US $1,740 1,694 2.7 % 2.7 % — %

Intl 2,537 2,354 7.8 6.3 1.5

WW 4,277 4,048 5.6 4.8 0.8

CONTACT LENSES / OTHER

US 1,378 1,337 3.1 3.1 —

Intl 1,669 1,565 6.6 5.5 1.1

WW 3,047 2,902 5.0 4.4 0.6

SURGICAL

US 363 358 1.4 1.4 —

Intl 867 789 10.0 8.0 2.0

WW 1,230 1,147 7.3 5.9 1.4

ORTHOPAEDICS

US 4,353 4,200 3.6 3.6 —

Intl 2,794 2,620 6.6 3.5 3.1

WW 7,146 6,820 4.8 3.6 1.2

HIPS

US 831 796 4.4 4.4 —

Intl 465 440 5.7 2.1 3.6

WW 1,296 1,235 4.9 3.6 1.3

KNEES

US 688 673 2.2 2.2 —

Intl 528 482 9.7 7.1 2.6

WW 1,216 1,155 5.3 4.2 1.1

TRAUMA

US 1,623 1,515 7.1 7.1 —

Intl 880 818 7.6 4.4 3.2

WW 2,504 2,333 7.3 6.2 1.1

SPINE, SPORTS & OTHER

US 1,211 1,216 (0.4) (0.4) —

Intl 920 881 4.5 1.5 3.0

WW 2,131 2,096 1.7 0.4 1.3

TOTAL MEDTECH

US 13,525 12,902 4.8 4.8 —

Intl 12,679 12,089 4.9 2.2 2.7

WW $26,204 24,991 4.9 % 3.5 % 1.4 %

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1)Operational growth excludes the effect of translational currency

(2)Unaudited

(3)Includes the sales of ZYTIGA which were previously disclosed separately

(4)Reported as U.S. sales

(5)Acquired with Intra-Cellular Therapies on April 2, 2025

GRAPHIC

Filename: image_1a.jpg · Sequence: 8

Binary file (339 bytes)

Download image_1a.jpg

GRAPHIC

Filename: jnjlogoa.jpg · Sequence: 9

Binary file (2962 bytes)

Download jnjlogoa.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.3

Cover

Oct. 13, 2026

Cover [Abstract]

Document Period End Date

Oct. 13, 2026

Document Type

8-K

Entity Registrant Name

Johnson & Johnson

Entity Incorporation, State or Country Code

Entity File Number

1-3215

Entity Tax Identification Number

22-1024240

Entity Address, Address Line One

One Johnson & Johnson Plaza

Entity Address, City or Town

New Brunswick

Entity Address, State or Province

Entity Address, Postal Zip Code

08933

City Area Code

732

Local Phone Number

524-0400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Document Information [Line Items]

Entity Emerging Growth Company

false

Entity Central Index Key

0000200406

Amendment Flag

false

Common Stock

Cover [Abstract]

Title of 12(b) Security

Common Stock, Par Value $1.00

Document Information [Line Items]

Title of 12(b) Security

Common Stock, Par Value $1.00

Trading Symbol

JNJ

Security Exchange Name

NYSE

Trading Symbol

JNJ

Security Exchange Name

NYSE

1.150% Notes Due November 2028

Cover [Abstract]

Title of 12(b) Security

1.150% Notes Due November 2028

Document Information [Line Items]

Title of 12(b) Security

1.150% Notes Due November 2028

Trading Symbol

JNJ28

Security Exchange Name

NYSE

Trading Symbol

JNJ28

Security Exchange Name

NYSE

1.650% Notes Due 2035

Cover [Abstract]

Title of 12(b) Security

1.650% Notes Due May 2035

Document Information [Line Items]

Title of 12(b) Security

1.650% Notes Due May 2035

Trading Symbol

JNJ35

Security Exchange Name

NYSE

Trading Symbol

JNJ35

Security Exchange Name

NYSE

3.20% Notes Due June 2032

Cover [Abstract]

Title of 12(b) Security

3.200% Notes Due June 2032

Document Information [Line Items]

Title of 12(b) Security

3.200% Notes Due June 2032

Trading Symbol

JNJ32

Security Exchange Name

NYSE

Trading Symbol

JNJ32

Security Exchange Name

NYSE

3.350% Notes Due June 2036

Cover [Abstract]

Title of 12(b) Security

3.350% Notes Due June 2036

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes Due June 2036

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

3.550% Notes Due June 2044

Cover [Abstract]

Title of 12(b) Security

3.550% Notes Due June 2044

Document Information [Line Items]

Title of 12(b) Security

3.550% Notes Due June 2044

Trading Symbol

JNJ44

Security Exchange Name

NYSE

Trading Symbol

JNJ44

Security Exchange Name

NYSE

2.700% Notes due February 2029

Cover [Abstract]

Title of 12(b) Security

2.700% Notes due February 2029

Document Information [Line Items]

Title of 12(b) Security

2.700% Notes due February 2029

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

3.050% Notes due February 2033

Cover [Abstract]

Title of 12(b) Security

3.050% Notes due February 2033

Document Information [Line Items]

Title of 12(b) Security

3.050% Notes due February 2033

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

3.350% Notes due February 2037

Cover [Abstract]

Title of 12(b) Security

3.350% Notes due February 2037

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes due February 2037

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

3.600% Notes due February 2045

Cover [Abstract]

Title of 12(b) Security

3.600% Notes due February 2045

Document Information [Line Items]

Title of 12(b) Security

3.600% Notes due February 2045

Trading Symbol

JNJ45

Security Exchange Name

NYSE

Trading Symbol

JNJ45

Security Exchange Name

NYSE

3.700% Notes due February 2055

Cover [Abstract]

Title of 12(b) Security

3.700% Notes due February 2055

Document Information [Line Items]

Title of 12(b) Security

3.700% Notes due February 2055

Trading Symbol

JNJ55

Security Exchange Name

NYSE

Trading Symbol

JNJ55

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDueMay2035Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueJune2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueJune2036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueJune2044Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A2.700NotesDueFebruary2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.050NotesDueFebruary2033Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueFebruary2037Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.600NotesDueFebruary2045Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.700NotesDueFebruary2055Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: